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Abstract
Bone morphogenetic protein (BMP) pathways control an array of developmental and homeostatic events, and must
themselves be exquisitely controlled. Here, we identify Caenorhabditis elegans SMA-10 as a positive extracellular regulator of
BMP–like receptor signaling. SMA-10 acts genetically in a BMP–like (Sma/Mab) pathway between the ligand DBL-1 and its
receptors SMA-6 and DAF-4. We cloned sma-10 and show that it has fifteen leucine-rich repeats and three immunoglobulin-
like domains, hallmarks of an LRIG subfamily of transmembrane proteins. SMA-10 is required in the hypodermis, where the
core Sma/Mab signaling components function. We demonstrate functional conservation of LRIGs by rescuing sma-10(lf)
animals with the Drosophila ortholog lambik, showing that SMA-10 physically binds the DBL-1 receptors SMA-6 and DAF-4
and enhances signaling in vitro. This interaction is evolutionarily conserved, evidenced by LRIG1 binding to vertebrate
receptors. We propose a new role for LRIG family members: the positive regulation of BMP signaling by binding both Type I
and Type II receptors.
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Introduction
Bone morphogenetic protein (BMP) receptor serine/threonine
kinases (BMPRs) are pivotal signal transducers for the small,
secreted BMP morphogens, members of the transforming growth
factor b (TGF- b) superfamily (comprising subfamilies of TGF- bs,
BMPs, activins, and others) [1,2]. BMP dimers released from
neighboring cells are received by these receptors, which leads to an
intracellular cascade of transcriptional events. Depending on the
specific pathway, cell type and milieu, these events result in a
diverse array of cellular processes, from dorsal-ventral specification
to cell cycle control and programmed cell death [3]. Understand-
ing how growth factor pathways are regulated may lead not only
to a better understanding of their normal physiological roles, but
may also lead to potential treatments for a wide range of disorders
and diseases [4,5].
Secreted BMP dimers travel through the extracellular matrix
to activate their receptors. Originally thought to be a process of
simple diffusion, the movement of TGF-b superfamily members
is now recognized to be highly regulated [6]. Many factors play
a role in facilitating or preventing BMP ligand access to
receptor. Post-translational processing and proteolysis of ligand,
as well as seclusion of ligand by extracellular matrix (ECM)
components like integrins and proteoglycans, for example,
determine whether a ligand dimer can interact with its receptors
[7]. Not only is the BMP’s progress exquisitely controlled, but
the receptors themselves are also subject to regulation [6,8].
Inside the cell, receptor phosphorylation is inhibited by
phosphatases, and SARA and Smurf proteins target receptors
for polyubiquitination and degradation [8]. Outside the cell, the
receptor complex can be inactivated by the decoy type I
receptor BAMBI [9]. Coreceptors betaglycan/TGFb receptor II
(TGFbR3) and endoglin can bind certain BMPS and deliver
them to receptors [10–14]. Endoglin also associates with select
type I and type II receptors [13].
Pioneer studies in Caenorhabditis elegans and Drosophila melanogaster
have identified components of the pathway and furthered
understanding of BMP signaling [15,16]. These studies have
identified the conserved core of the signaling pathway, including
the ligand, the type I and type II receptors, and the Smads. In C.
elegans, a BMP-like pathway controls body size and male tail
development (the Sma/Mab pathway). The receptors for the
ligand DBL-1 are SMA-6 (type I) and DAF-4 (type II) [17,18].
Receptor signals are transduced through the Smads SMA-2,
SMA-3, and SMA-4 [19]. As in mammals, co-transcription factors
that act with the Smads have been discovered, including SMA-9/
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of the Sma/Mab pathway is very sensitive to dose, indicating that
the core pathway is tightly controlled [17,18,22,23]. The only
identified extracellular regulator of this pathway has been LON-2,
a conserved heparan sulfate proteoglycan that binds DBL-1/BMP
and attenuates pathway signaling [24].
To identify novel components of BMP signaling, we performed
traditional forward genetic screens for mutations affecting the Sma/
Mab signaling pathway ([25], unpublished results). From these
genetic screens, we identified, cloned, and characterized sma-10.
SMA-10 is a positive regulator of Sma/Mab signaling, and is
absolutely and specifically required for body size regulation. It is a
member of a cell surface localized family of proteins with leucine rich
repeats and immunoglobulin-like domains (LRIG). The function of
SMA-10 in BMP pathway signaling is conserved, as the Drosophila
ortholog lambik rescues the body size defect of sma-10(lf) animals.
Furthermore, SMA-10 promotes BMP signaling in mammalian cells.
SMA-10 binds the pathway receptors SMA-6 and DAF-4 but not the
BMP DBL-1, and a mammalian ortholog, LRIG1 (leucine-rich and
immunoglobulin-like domains-1), also binds both type I and type II
receptors. These studies identify a uniquely acting positive regulator
of BMP signaling, SMA-10/LRIG, that directly interacts with type I
and type II receptors from C. elegans to mammals.
Results
sma-10(lf) Alleles Were Identified in Screens for Small
Body Size
The first small C. elegans mutants were identified in a large-scale
screen for morphology and mobility mutants [26]. Their role in BMP
signaling was elucidated when sma-2, sma-3 and sma-4 were
characterized [19]. In an effort to identify additional genes that act
in BMP signaling, we performed two genetic screens. From the first
screen, in which body size mutant F2 animals were isolated from
mutagenized N2/wild type P0 animals, two sma-10 alleles, wk26 and
wk66, were identified [25]. From a lon-2(e678) suppressor screen,
three additional alleles, wk88, wk89,a n dwk90,w e r ei d e n t i f i e da n d
confirmed by complementation and sequencing.
sma-10 Mutants Display Body Size Defects But No Male
Tail Abnormalities
The Sma/Mab pathway regulates both body size and male tail
development. A reduction of dbl-1 p a t h w a ya c t i v i t yr e s u l t si na n i m a l s
that are 55%–85% wild-type length [22,23]. sma-10(lf) animals share
the small body size defect, ranging from 79% to 88% the length of
wild-type animals (Figure 1A and 1B, Table 1). The dbl-1 pathway
also regulates the development and patterning of male tail structures
[17–19,22,23], with mating spicules and sensory rays 5–7 being
primarily affected. We therefore asked if sma-10 is also involved in
patterning the male tail. Our studies revealed that all five alleles of
sma-10, including a presumed null (wk88), have wild-type male tail
rays and spicules (data not shown). These data suggest that SMA-10 is
specifically involved in BMP signaling to control body size but not
male tail development or patterning.
SMA-10 Acts in the Sma/Mab Pathway
Because small body size is a hallmark phenotype of mutants in
the Sma/Mab pathway, we asked if sma-10 genetically interacts
Author Summary
Bone morphogenetic protein (BMP) family members, small
secreted signaling molecules, play diverse roles in devel-
opment and homeostasis. Uncontrolled BMP signaling
results in a variety of disorders and diseases. BMPs signal
to receiving cells through two receptor types, which act
together to propagate the BMP signal within cells. To
understand how BMP signaling is controlled, we used the
nematode Caenorhabditis elegans to identify conserved
regulators of BMP signaling. Here, we characterize SMA-10,
the first extracellular positive regulator of DBL-1/BMP
receptor-mediated signaling. SMA-10 is a new member of
a family with leucine rich repeats and immunoglobulin-like
domains (LRIG). SMA-10 physically binds the two types of
DBL-1/BMP receptor. We demonstrate conservation of
LRIG function by showing that a Drosophila melanogaster
LRIG can functionally substitute for loss of C. elegans SMA-
10/LRIG, that C. elegans SMA-10 can directly promote
mammalian BMP signaling in cells, and that mammalian
LRIG1 interacts with BMP receptors. Our work establishes a
role for LRIGs in BMP regulation through binding both
types of BMP receptor.
Figure 1. sma-10 is required for normal body size. Microscope images of (A) a wild-type (N2) hermaphrodite and (B) a sma-10(wk66)
hermaphrodite, both taken at 24 hours after the L4/adult molt (same magnification on a dissecting microscope, scale bar represents 0.1 mm). SMA-
10:GFP is expressed in hypodermis (D) and pharynx muscle (E). No hypodermal fluorescence was detected in non-transgenic animals (C). Weak
expression was detected in hypodermis (20-fold longer exposure of image in (C) than (D)). Arrows point to hypodermis in (C,D). Arrowheads point to
the end of the intestine in (C,D). Intestinal autofluorescence is visible to the left of the arrowheads in (C,D). Strong expression of the SMA-10:GFP full-
length fusion construct was observed in the pharynx muscle. Expression of the ttx-3::rfp marker in the AIY neuron is also visible in the upper right
corner (E). Scale bars in (C–E) represent 0.01 mm. Anterior is to the left in all panels.
doi:10.1371/journal.pgen.1000963.g001
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order of SMA-10 relative to Sma/Mab pathway members, we
performed epistasis tests. We generated animals with mutations in
sma-10 and DBL-1/BMP pathway genes that alone give opposite
phenotypes (small and long, respectively), and asked what the
terminal phenotype was for these strains (small or long). In a
regulatory pathway, the terminal phenotype is a result of the loss of
gene product with the most downstream effect bypassing the
requirement for the second, upstream gene product. We created
double mutant animals of sma-10 with lon-2, overexpressed dbl-1,
or over expressed sma-6. We found that the small body size
phenotype of sma-10(lf) was the terminal phenotype in double
mutant animals with either lon-2 or over expressed dbl-1, but not
for overexpressed sma-6 (Table 2). These results suggest that SMA-
10 functions in the unique position between the receptor SMA-6
and the ligand DBL-1.
sma-10 Encodes a Protein with Leucine-Rich Repeats and
Immunoglobulin-Like Domains
To understand the molecular nature of sma-10, we mapped and
cloned the gene. sma-10 is located at LG IV: 226.82. Cosmid
T21D12 conferred rescue of the sma-10(wk66) small phenotype, as
does a sma-10 cDNA (Table S1). sma-10 encodes an 881 amino
acid protein of the LRIG family (leucine rich repeats and
immunoglobulin-like domains). SMA-10 is composed of an N-
terminal signal sequence (amino acids 1–20), fifteen leucine-rich
repeats (LRRs) flanked by an LRR N-terminal domain at amino
acids 24–56 and an LRR C-terminal domain ending at amino acid
499, three immunoglobulin domains (spanning amino acids 503 to
802), a transmembrane domain (amino acids 839 to 861), and a
short (19 amino acid) intracellular domain from amino acids 862
to 881 (Figure 2). The C-terminal tail is not conserved between C.
elegans, Drosophila and mammals. This protein structure, which is
largely extracellular and is transmembrane-bound, is consistent
with the order of gene function, which places SMA-10 between the
secreted DBL-1/BMP and its membrane-bound receptors.
Sequencing DNA of mutant sma-10 strains confirmed lesions
within T21D12.9 (Figure 2). sma-10(wk26) contains a T to C bp
change at position 572, a substitution that changes a conserved
leucine to a phenylalanine in the second LRR at amino acid 102.
A deletion of 251 bps generates sma-10(wk66) (on cosmid T21D12
from base pairs 21092 to 21342, beginning in the gene at the end
of exon 9). This transcript is predicted to result in a truncated
protein with 609 a.a. of SMA-10 and 10 a.a. of novel sequence
before terminating, deleting sequences after the first immunoglob-
ulin-like domain. wk88 introduces a stop codon into amino acid
position 112 in the LRR2, resulting in a severely truncated
protein, and is a presumed null allele. wk89 is a 975 bp deletion
from position 21301 to 22275 in T21D12, starting in intron 9 and
ending in intron 11, deleting the protein after amino acid 611 and
creating a frame shift and premature termination sequence,
removing sequences after the first immunoglobulin-like domain.
wk90 changes sequence encoding Trp 286 to a stop codon,
deleting sequences after LRR9.
Multiple splice variants are predicted by cDNA sequencing
(Wormbase.org). yk352c5, a full-length 2.6 kb cDNA of the
longest splice variant T21D12.9a, driven by 1.2 kb of upstream
sma-10 promoter sequence, is sufficient to confer rescue of sma-
10(wk66) animals (Table S1). A function for the shorter splice
variants (T21D12.9b, T21D12.9c.1, and T21D12.9c.2) is not
known.
Database searches reveal orthologs in other metazoans. The
hallmark of this family is the presence of fifteen leucine-rich
repeats (LRRs) and three immunoglobulin-like repeats (Ig-like)
followed by a transmembrane domain. In Drosophila, there is one
SMA-10 ortholog, Lambik (www.flybase.org), and in vertebrates,
there are three known sma-10 orthologs, LRIG1, LRIG2, and
LRIG3 [27]. lambik corresponds to CG8434, but no phenotypic
characterization has been published. A distantly related, distinct
family is composed of the insect-specific Kekkon members, which
have six LRRs and one Ig–like domain. One of these, Kekkon 1
(kek1), plays a role in inhibiting the epidermal growth factor
receptor (EGFR) [28]. Another Kekkon, Kekkon5 (kek5), interacts
genetically with a BMP signaling pathway [29].
sma-10 Is Required in the Hypodermis to Regulate Body
Size
Although core Sma/Mab pathway components are expressed in
many tissues, they are all required in the hypodermis for body size
regulation. To determine if SMA-10 is also needed in these cells,
Table 1. Quantitation of sma-10 mutant body size.
genotype p value % WT n
wild type 100614 6
sma-10(wk26) ,0.001 88624 6
sma-10(wk66) ,0.001 81624 1
sma-10(wk88) ,0.001 79624 2
sma-10(wk89) ,0.001 82622 6
sma-10(wk90) ,0.001 83623 7
Body perimeters of staged one-day adult hermaphrodites were measured. The
p value is the probability that the null hypothesis, that the mean body length of
each sma-10 mutant line is the same as the wild-type mean body length, is true.
‘‘% WT’’ is the ratio of the indicated strain mean to the wild-type strain mean
695% confidence interval. n, number of animals measured.
doi:10.1371/journal.pgen.1000963.t001
Table 2. sma-10 acts between ligand dbl-1 and receptor
sma-6.
genotype p value % WT n
wild type - 100633 3
sma-10(wk66) ,0.001 84633 1
sma-10(wk89) ,0.001 82622 6
lon-2(e678) ,0.001 114622 9
sma-10(wk89); lon-2(e678) 0.035
a 79622 3
ctIs40 (dbl-1(+)) ,0.001 125641 7
sma-10(wk66); ctIs40 (dbl-1(+)) .0.5
b 84623 0
sma-6(wk7) ,0.001 77633 1
sma-6(wk7); texEx190 (sma-6(+)) ,0.001
c 88633 1
sma-10(wk66); texEx190 (sma-6(+)) ,0.001
b 99651 2
aCompared to sma-10(wk89).
bCompared to sma-10(wk66).
cCompared to sma-6(wk7).
ctIs40 is an integrated array that overexpresses a cosmid fragment containing
wild-type dbl-1 promoter and gene. texEx190 is an extrachromosomal array that
drives expression of a functional SMA-6:GFP fusion protein from the sma-6
promoter. The p value is the probability that the null hypothesis, that the mean
body length of each mutant line is the same as the background body length, is
true. ‘‘% WT’’ is the ratio of the indicated strain mean to the wild-type strain
mean 695% confidence interval. n, number of animals measured.
doi:10.1371/journal.pgen.1000963.t002
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translational fusion of SMA-10 with GFP at the C-terminus and
expressed it using the sma-10 promoter. Expression of SMA-
10:GFP was visible, though faint, in the hypodermis (Figure 1C
and 1D), consistent with SMA-10’s genetically identified role as a
regulator of the DBL-1 signaling pathway, which functions in the
hypodermis to regulate body size. Expression in the hypodermis of
other DBL-1 pathway genes is also low [24,30–33].
Bright fluorescent expression was also observed in the pharynx
of animals from embryos to adults (Figure 1E). Pharyngeal
expression was localized to the muscle segments pm1 (anterior cell
of the procorpus), pm4 (metacarpus/anterior bulb), the anterior
part of pm5 (isthmus), and pm7 (terminal bulb) (Figure 1E).
Expression of SMA-10:GFP localized to both the cell surface and
to puncta within the cells (Figure 1E). Expression of mRNA
corresponding to the sma-10 locus has also been reported in
intestine and renal gland cells in both larvae and adult animals
[34]. Digestive tract expression (in the pharynx and intestine) of
other Sma/Mab pathway members has been reported
[18,32,33,35,36], and may reflect a proposed role for this pathway
in an innate immune response [37,38].
We then asked where SMA-10 is required for body size
regulation. Because of its expression pattern and previous
experiments showing that DBL-1/BMP pathway components
are required in the hypodermis, we drove the expression of full-
length genomic sma-10 from pharyngeal- or hypodermal-specific
promoters in sma-10(wk66) animals and assayed for rescue of body
size. We found that expression of sma-10(+) in hypodermis (using
the rol-6 promoter), but not pharynx (using the myo-2 promoter),
was sufficient to rescue animals to wild-type length (Table 3).
Drosophila LRIG lambik Rescues sma-10(lf) Animals
Lambik is a Drosophila LRIG that is orthologous to vertebrate
LRIGs and to SMA-10. Although the function of Lambik is
currently unknown, we asked whether lambik could functionally
substitute for sma-10 in C. elegans. We drove Drosophila lambik cDNA
from the sma-10 promoter in sma-10(wk66) animals. Transgenic
animals were rescued to the wild-type body size (Table 4), thereby
showing functional conservation between divergent Drosophila and
C. elegans LRIGS.
SMA-10 Promotes BMP Signaling in Mammalian Cells
Our genetic data demonstrate that SMA-10 acts within a
nematode BMP-like pathway to promote signaling. To test
whether this function is conserved, we asked if SMA-10 could
regulate BMP signaling in mammalian cells. We used a standard
reporter assay in a BMP-responsive human cell line (HepG2), the
BMP-response element from the Smad7 gene driving luciferase
[39]. BMP2 induced reporter activity significantly over the
controls, whereas in the presence of SMA-10, the response of
the promoter was increased 4.2-fold over BMP2 alone (Figure 3A).
Thus, SMA-10 can directly promote mammalian BMP signaling.
SMA-10 Binds BMP Receptors SMA-6 and DAF-4
The genetic and molecular data strongly support a model in
which SMA-10 acts on the extracellular surface of the plasma
membrane, and could act via physical interactions with ligand,
receptors, or ligand and receptors. To examine these possibilities
and to provide mechanistic insights into SMA-10’s function, we
asked whether SMA-10 directly binds to ligand or to the DBL-1
receptors, SMA-6 and DAF-4. For the first experiment, we
employed affinity labeling and substituted BMP2 for DBL-1, since
Figure 2. Structural comparison of SMA-10 to Drosophila Lambik and mammalian LRIGs. Schematic diagram of C. elegans SMA-10,
Drosphila Lambik, human LRIG1, LRIG2, and LRIG3 and Drosophila Kekkon 1. Domains/motifs are represented as follows: N-terminal signal sequences,
light gray rectangles; leucine rich repeat N- and C-terminal domains, medium gray ovals; leucine-rich repeats, dark gray ovals; immunoglobulin-like
domains, black boxes; and transmembrane domains, striped rectangles. Arrows above the C. elegans protein sequence indicate mutations affecting
the SMA-10 protein. Domains were placed according to SMART analyses [62], Guo et al (LRIGs) [27], and MacLaren et al (Kekkon 1) [63].
doi:10.1371/journal.pgen.1000963.g002
Table 3. Hypodermal sma-10 expression rescues the body
size defect of sma-10(lf) animals.
Genotype p value % WT n
wild type - 100623 5
sma-10(wk66) ,0.001 84633 1
sma-10(wk66);wkEx91 (myo-2p::sma-10(+)) pharynx .0.5
a 84631 1
sma-10(wk66);wkEx92 (rol-6p::sma-10(+)) hypodermis ,0.001
a 98633 8
acompared to sma-10(wk66).
The myo-2 promoter drives pharyngeal expression, and the rol-6 promoter
drives hypodermal expression. The p value is the probability that the null
hypothesis, that the mean body length of each mutant line is the same as the
background body length, is true. ‘‘% WT’’ is the ratio of the indicated strain
mean to the wild-type strain mean 695% confidence interval. n, number of
animals measured.
doi:10.1371/journal.pgen.1000963.t003
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to physically interact with other DBL-1 pathway members [17,24].
SMA-10 was FLAG-tagged and BMP2 ligand was radio-iodinated
with
125I. After anti-FLAG immunoprecipitation and blotting, the
blot was exposed to film. However, we failed to detect any binding
of BMP2 to SMA-10 (Figure S1). We next asked whether SMA-10
interacted with the receptors. FLAG-tagged SMA-10 and HA-
tagged receptors were transfected into 293T cells. To isolate SMA-
10 and associated proteins from cells, lysates were first immuno-
precipitated with anti-FLAG antibody and blotted. The blot was
then probed with anti-HA antibody to determine whether
receptors were bound to SMA-10. Under these conditions, both
SMA-6 and DAF-4 receptors co-immunoprecipitated with SMA-
10 (Figure 3B). Thus, SMA-10 physically interacts with receptors
and not with the ligand.
Figure 3. SMA-10 binds BMP receptors and enhances BMP signaling. SMA-10 enhances BMP signaling in HepG2 cells (A). Cells were
transfected with a BMP-responsive transcriptional reporter (I-BRE:luciferase) and either SMA-10 or a control vector. Cells were either left unstimulated
(black bars) or were stimulated with 2.5 nM BMP2 (grey bars). The average of four transfected wells is shown plus and minus the standard deviation.
SMA-10 binds SMA-6 and DAF-4 (B). 293T cells were co-transfected with FLAG-tagged SMA-10 and HA-tagged SMA-6 or DAF-4 receptors. Lysates
were immunoprecipitated with anti-FLAG (SMA-10) and blotted for HA (SMA-6 or DAF-4). LRIG1 is able to interact with several mammalian BMP
receptors (C). Cells were co-transfected with various HA-tagged BMP receptors and 3x FLAG-tagged LRIG1, then lysates were immunoprecipitated
with anti-HA antibody and blotted with anti-FLAG to detect LRIG1.
doi:10.1371/journal.pgen.1000963.g003
Table 4. Drosophila lambik rescues the body size defect of
sma-10(lf) animals.
Genotype p value % WT n
wild type - 100623 9
sma-10(wk66) ,0.001 84633 1
sma-10(wk66); wkEx93 (sma-10p::lambik) ,0.001
a 97634 9
aCompared to sma-10(wk66).
The p value is the probability that the null hypothesis, that the mean body
length of each mutant line is the same as the background body length, is true.
‘‘% WT’’ is the ratio of the indicated strain mean to the wild-type strain mean
695% confidence interval. n, number of animals measured.
doi:10.1371/journal.pgen.1000963.t004
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Given that SMA-10 binds the Sma/Mab pathway receptors, we
tested whether this interaction was conserved in a mammalian
system. Using the mammalian ortholog LRIG1 and mammalian
BMP receptors, we assayed the ability of LRIG1 to bind the
receptors. FLAG-tagged LRIG1 and HA-tagged versions of BMP
receptors were transfected into mammalian cells. Lysates were
immunoprecipitated with anti-FLAG antibody to pull down
LRIG1, blotted, and probed with anti-HA antibody to determine
whether LRIG1 binds any BMP receptors. We found that LRIG1
interacted strongly with type I receptor ALK6 and more weakly
with the type I receptors ALK1, ALK2, ALK3, and ActRIB
(Figure 3C). In addition, we detected weak interactions with type
II receptors ActRII and ActRIIB (Figure 3C). Thus, LRIGs
interact with BMP receptors and represent a new class of BMP
receptor-associated proteins.
Discussion
Here we describe a conserved, novel regulator of BMP
signaling, SMA-10, which is absolutely required for body size
signaling in C. elegans. Loss of SMA-10 function results in a
phenotype similar to a loss of any of the Sma/Mab pathway
components. Molecular and genetic analyses place its function at
the level of the cell membrane between the ligand and the
receptors. Several lines of evidence support a model in which
SMA-10 and its orthologs are conserved regulators of BMP
signaling. The Drosophila homolog lambik rescues sma-10(lf)
animals. Consistent with genetic evidence that SMA-10 is a
positive effector of BMP signaling, SMA-10 stimulates a positive
BMP-specific response in human cells. Furthermore, SMA-10 and
LRIG1 physically interact with BMP type I and type II receptors.
LRIGs have previously been shown to regulate EGF and Met
receptor tyrosine kinase signaling [40,41], and recently the insect-
specific kekkon5 was shown to genetically interact with a BMP
signaling pathway [29]. Our work reveals a new, conserved role
for the LRIG subfamily in BMP receptor signaling.
SMA-10 Acts in BMP Signaling in C. elegans
We propose that SMA-10 acts at the hypodermal membrane
surface, where the Sma/Mab receptors are located, to facilitate
receptor signaling. Our genetic evidence shows that the SMA-10
protein acts between the secreted ligand and the transmembrane
receptors (Table 2). The structure of SMA-10 indicates that it
contains a secretion signal and a transmembrane region (Figure 2).
Subcellular localization of a rescuing translational SMA-10:GFP
fusion shows SMA-10 in hypodermal tissues and at cell membrane
surfaces (Figure 1C and 1E). The requirement for sma-10
expression in the hypodermis to rescue the sma-10(lf) small body
size further supports the model that SMA-10 acts at the
hypodermal membrane to facilitate DBL-1 binding to its receptors
(Table 3). We predict that the extracellular domain is responsible
for this rescuing effect, as SMA-10’s C-terminal intracellular tail is
short (19 amino acids) and not conserved with Lambik, which has
SMA-10 function, and SMA-10 is able to rescue when tagged with
GFP at the C-terminus. We suggest that this intracellular sequence
is not critical for transducing BMP signals.
Mutant animals for all previously characterized Sma/Mab core-
signaling components have alterations in both body size and male tail
defects. However, sma-10 only affects body size. This can be
explained if sma-10 acts in a tissue-specific manner, namely the
hypodermis, where DBL-1activated pathway signaling is required for
body size control. Previous studies of targets downstream of this
pathway (lon-1, mab-21,a n dmab-23) and one upstream regulator
(LON-2) have shown that functions in the body size and male tail
pathways are separable [22,24,30,31,42]. Given that sequencing
reveals that one of the sma-10 alleles (wk88) is a presumed null, we
favor the model that SMA-10 acts in a tissue-specific manner to
enhance signal strength in the cells contributing to body size but not
to the male tail. Consistent with this reasoning, differences in the
requirement of signal strength between the tail and the hypodermis
are seen with a hypomorphic allele of sma-6, where body size is
reduced while tail morphology is normal [18]. It remains to be seen
whether differential responses to Sma/Mab pathway dosage
differences are sufficient to explain this tissue specificity or if there
exists another male-specific factor that functions, like SMA-10 in the
hypodermis, to positively regulate Sma/Mab signaling in the male
tail. We note that all the sma-10 alleles result in small animals that are
not as small as animals with loss-of-function mutations in previously
identified core-signaling components. If tissue specificity in other
o r g a n i s m si sac o m m o nf e a t u r e ,t h e nt h i sc o u l de x p l a i nw h ysma-10
orthologs were not previously identified as BMP signaling modula-
tors.WenotethatmammalshavethreeLRIGs,andmutatingasingle
LRIG (LRIG1, a.k.a. LIG-1) results in a mild hyperplasia of
epidermal cells [43]. This is a seemingly minor defect, but loss of
LRIG1 function may be partially compensated by the other two
functional LRIGs. Therefore, redundancy may also explain why
LRIGs have eluded identification as regulators of BMP signaling in
higher organisms.
SMA-10 Is a Conserved LRIG Family Member
The LRR and Ig-like domains exist singly in many other
proteins, but only in the LRIG family do they exist in the same
protein. The number of protein domains in the SMA-10/LRIG
family, which excludes the insect Kekkon subfamily, is invariant.
These domains have been shown to be involved with protein-
protein interactions [44,45]. In these studies, we show that SMA-
10 and LRIG1 bind BMP type I and type II receptors, and our
genetic evidence and studies based on overexpression in
mammalian cells suggests that these proteins are positively
required for BMP family signal transduction.
Kekkon 1 has been shown to be a negative regulator of the EGF
pathway in Drosophila and acts by binding to the receptors [28].
Given the involvement of Kekkon 1 in EGF signaling, LRIG1 was
tested for EGFR regulation in mammalian tissue culture [40].
LRIG1 was shown to also bind EGFRs and enhance their
degradation [40]. Signaling of EGFs through EGFRs promotes
cell proliferation. LRIG1 negatively regulates cell proliferation by
down-regulating EGFR responsiveness by increasing activated
receptor ubiquitination [28,40]. LRIG1 binds the E3 ubiquitin
ligase c-Cbl, bringing it into the EGFR complex. EGFR then
phosphorylates c-Cbl, thereby activating it and promoting
ubiquitination and degradation of both LRIG1 and EGFRs.
LRIG1’s amino acids 900 to 930 contain the binding site for c-Cbl
[40], within its intracellular domain that is not shared by other
LRIGs, SMA-10, or Lambik. An interaction of c-Cbl with LRIG2
or LRIG3 has not been demonstrated [46]. The ectodomain of
LRIG1 alone inhibits EGFR signaling, but does so in a ubiquitin-
independent fashion, showing that EGFR inhibition by LRIGs is
not exclusively through ubiquitination [47]. EGFR signaling in C.
elegans, mediated by a single EGFR (LET-23), directs several
embryonic and larval cell fates and also ovulatory contractions in
adult hermaphrodites [48]. We did not see any obvious defects
associated with EGFR in sma-10(lf) animals that might suggest an
interaction with EGFR. LRIG1 also binds to and inhibits signaling
by hepatocyte growth factor receptor (Met), a tyrosine kinase that
in many known cancers is mutated or misregulated to promote
invasive growth, though its mechanism of inhibition is ubiquitin-
SMA-10/LRIG Positively Regulates BMP Signaling
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tyrosine kinase [49]. Another Kekkon, Kekkon5, affects BMP
signaling, but the model, based on genetic and structure-function
analyses, proposes that Kekkon5 regulates ligand distribution or
activity rather than acts directly on receptors, as we show here for
both C. elegans LRIG SMA-10 and mammalian LRIG1 [29].
Although their expression appears to be universal, human LRIGs
are differentially expressed in various cancer cell types, being down
regulated in many types studied, but being upregulated in others[46].
Various explanations have been proposed based on the current
understanding of LRIG function [46]. Our research showing LRIG
interaction with BMP receptors (BMPRs) leads us to propose a new
model, where the cell-specific levels of BMP and EGF activity, which
negatively and positively regulate cell growth, respectively, determine
the cell’s response to LRIG exposure.
The observation that SMA-10 localizes to intracellular puncta
(Figure 1C) is reminiscent of endocytic vesicles, and suggests a
model of action for SMA-10 and the Sma/Mab signaling pathway
[50]. In other systems, there is evidence that TGF-b superfamily
pathway signaling can be activated via receptor monoubiquitina-
tion and receptor complex endocytosis into early vesicles (reviewed
in [51,52]). SMA-10 may thus promote signaling by facilitating
receptor internalization into early endosomes.
This work identifies a new, conserved component of BMP
signaling, SMA-10/LRIG. Mammalian members play known
roles in some receptor tyrosine kinase pathways, and this work
identifies a new role for this family in BMP receptor serine/
threonine kinase signaling. We have shown that two members of
this family physically interact with both the type I and type II BMP
receptors, and C. elegans SMA-10 enhances signaling in both the
nematode and in mammalian cells.
Materials and Methods
Strains
Animals were maintained according to standard protocols [26].
All mutant strains used in this study were derived from the wild-
type Bristol strain N2, and some mapping was accomplished using
the wild-type Hawaii isolate CB4856. Alleles used include sma-
10(wk26, wk66, wk88, wk89, wk90) [25], lon-2(e678), sma-6(wk7),
ctIs40 [ZC421 (dbl-1(+)) + pTG96 (sur-5::gfp)] [23], bxIs16 [tph1::gfp
+ cat-2::yfp] [42]; and nIs128 [pkd-2::gfp] [53]. Arrays made for this
study are wkEx47 (sma-10p::sma-10:gfp + pUC18 filler DNA,
50 ng/ml each), wkEx91 (myo-2p::sma-10(+)), wkEx92 (rol-6p::sma-
10(+)), wkEx93 (sma-10p::lambik), texEx190 (sma-6p::sma-6(+):gfp),
and texEx195 (sma-10p::sma-10(yk352c5).
Creation of transgenic arrays was performed by standard
microinjection techniques [54]. Genomic sma-10 or Drosophila
lambik cDNA was cloned into nematode expression vector
pPD95.75 with the appropriate promoter sequence. wkEx47 was
made by removing the stop codon of the sma-10 genomic sequence
and fusing the gfp sequence in-frame at the 39 end. Transgenic
animals were generated by germline microinjection, using
constructs at 50 ng/ml (HW480 sma-10p::lambik, CZ10.2 sma-
10p::sma-10:gfp, and CZ9.1 sma-10(yk352c5)) or 0.5 ng/ml (HW469
rol-6p::sma-10 and HW477 myo-2p::sma-10) with the co-injection
marker ttx-3p::rfp or ttx-3p::gfp at 50 ng/ml (with HW480 and
CZ9.1) or 100 ng/ml (with HW469 and HW477). ttx-3p drives
expression in AIY interneurons. One representative stable line for
each transgene was measured.
Isolation of sma-10 Mutant Animals
Isolation of sma-10(wk26) and sma-10(wk66) was previously
described [25]. In an effort to identify additional alleles of genes
that act BMP signaling, lon-2(e678) hermaphrodites were muta-
genized with 50 mM ethyl methanesulfonate (EMS) using
standard procedures [26]. Mutagenized P0 animals were trans-
ferred to plates and allowed to segregate self-progeny. F1 animals
were transferred to new plates to segregate progeny, which were
then scored for a small phenotype in a quarter of the population.
From about 9,000 mutagenized genomes screened, three addi-
tional alleles of sma-10 were isolated, wk88, wk89, and wk90. These
alleles, as well as the two alleles isolated in the Sma screen [25],
were outcrossed five times before further analyses were done.
Phenotypic Analyses
To measure body size, animals were picked at the L4 stage and
photographed as young adults about 24 hours later. Images from
individual animals were captured from a dissecting microscope
using an Optronics MagnaFire CCD camera system and software
(Optronics, Goleta, CA). Perimeters (Table 1) or lengths (Table 2,
Table 3, Table 4) of animals were determined by using Image-Pro
Plus measurement software (Media Cybernetics, Inc., Silver
Spring, MD). The images for Figure 1C and 1D were captured
using an Axiovert 200 M microscope (Carl Zeiss MicroImaging,
Oberkochen, Germany) equipped with a digital CCD camera
(C4742-95-12ER, Hamamatsu Photonics, Hamamatsu, Japan)
and were deconvolved with AutoDeblur software (AutoQuant
Imaging, Watervliet, NY). The Figure 1E image was obtained on
an Olympus IX81 with a Carv Nipkow disk confocal unit (Atto
Biosciences, Rockville, MD) and SensiCam QE camera (Cooke
Corp., Auburn Hills, MI).
We performed statistical analyses on these measurements.
Individual measurements from each strain were averaged. We
determined the ratio and 95% confidence interval of the average
measurement (mean) of each strain to the wild-type strain mean.
To verify the significance of our findings, we tested the null
hypothesis that the ratios of the compared means are the same.
The ratios compared were the double mutant strain mean/wild
type mean to the single sma/transgenic mutant strain mean/wild
type strain mean. For populations measured on the same day, the
denominator (the average of wild-type measurements) was the
same and a Student’s t-test was used to test the null hypothesis. For
populations measured on different days, the Welch-Satterthwaite
equation was used to calculate the effective degrees of freedom for
this 2-tailed t-test for two ratios. We determined the value of t with
the calculated degrees of freedom and compared the t-value to the
Student’s t table to construct the probability (p) of the null
hypothesis.
Epistasis Analyses
sma-10(wk66); lon double mutant animals were constructed by
crossing heterozygous sma-10(wk66) males with lon-2(e678) or lon-
1(wk50) hermaphrodites, with animals overexpressing an integrat-
ed transgene with wild-type dbl-1 (ctIs40), or with animals
overexpressing an extrachromosomal array encoding functional
SMA-6 (texEx190) [15]. Wild-type F1 were isolated and small and
long F2 animals were picked to individual plates. The F3
generation was then examined for the presence of long animals
from a small F2 parent or small animals from a long F2 parent.
Positional Cloning of sma-10
sma-10(wk66) was previously mapped to chromosome IV by
two-factor crosses [25]. We further refined its position by standard
three-factor mapping and single nucleotide polymorphism map-
ping [26,55]. We used microinjection and germline transformation
rescue [54] to discover that YAC Y80C9 and cosmid T21D12
rescue the small phenotype of sma-10(wk66) animals. Each
SMA-10/LRIG Positively Regulates BMP Signaling
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sequence, was amplified by the polymerase chain reaction (PCR).
The DNA product was purified and injected into sma-10(wk66)
animals. Only T21D12.9 rescued the small phenotype. PCR
confirmed altered or deleted sequences in all five sma-10 alleles.
Cell Culture
293T cells were cultured in Dulbecco’s modified Eagle’s
medium containing high glucose and supplemented with 10%
fetal bovine serum (FBS). HepG2 cells were cultured in minimal
essential media supplemented with 1% non-essential amino acids
and 10% FBS. Cells were transfected by calcium phosphate and
lysed 48 hours after transfection in TNTE buffer containing 0.5%
Triton-X-100 (150 mM NaCl, 50 mM Tris ph 7.4, and 1 mM
EDTA) [56]. Immunoprecipitations were carried out using M2
anti-FLAG (Sigma) or 12CA5 anti-HA (made in-house) followed
by incubation with Protein-G Sepharose beads (Amersham
Biosciences, Uppsala, Sweden). Immunoprecipitates were then
washed four times with lysis buffer containing 0.1% Triton-X-100.
Proteins were separated by SDS-PAGE and immunoblotted with
anti-HA (12CA5) or anti-FLAG (M2).
Signaling Assays
Transcriptional assays were carried out using a previously
described BMP-responsive element from the mouse Smad7 gene
(I-BRE) driving firefly luciferase [39]. Luciferase assays were
carried out as described [39]. Renilla luciferase expressed from the
CMV promoter was used as an internal control for transfection
efficiency. Firefly luciferase values were normalized using Renilla
luciferase values.
Constructs
1.2 kb promoter sequence 59 of the sma-10 open reading frame
driving expression of genomic sma-10 was sufficient to rescue body
size defects in sma-10(lf) animals, and this same promoter region
was fused to Drosophila lambik/CG8434 cDNA to address
conservation of LRIG family function. Tissue specific expression
was determined by driving expression of sma-10 genomic sequence
with myo-2 (pharyngeal expression) or rol-6 (hypodermal expres-
sion) promoters [57]. We generated GFP-tagged SMA-10 by
fusing the eGFP sequence to the 39 terminus of wild-type sma-10
genomic sequence that lacked its termination codon.
The rescuing sma-6 construct was made by fusing the mCherry
sequence in frame to the 39 end of genomic sma-6 and expressing it
using 1260 bp sma-6 promoter sequence.
3x FLAG SMA-10 was made by fusing the full-length sma-10
cDNA from the first Sal I site in frame to the 3x FLAG signal peptide
containing vector p3xFLAG-CMV8 (Sigma). Similarly, we con-
structed the 3x FLAG-tagged LRIG-1 by subcloning the LRIG
cDNA from an endogenous Sal I restriction site to the C-terminus
into p3xFLAG-CMV8. This construct encodes a protein with the 3x
FLAG tag between the N-terminal signal sequence and the first LRR
of LRIG1. SMA-6 was C-terminally tagged with the HA1 epitope of
influenza virus hemagglutinin (HA) and was cloned into the
mammalian expression vector pCMV5 (T. Reguly and J. Wrana,
unpublished work). DAF-4DC-HA is HA-tagged DAF-4 with a
deletion of its C-terminal tail (T. Reguly and J. Wrana, unpublished
work). ALKIHA, ALK3HA, ALK6HA, ALK2HA, ActRIBHA,
ActRIIHA, ActRIIBHA have been previously described [58–61].
Supporting Information
Figure S1 SMA-10 does not bind BMP ligands. HepG2 cells
were transfected with either HA-tagged DAF-4, the control vector,
or HA-tagged SMA-10 and incubated with 0.5 nM
125I-BMP2.
Lysates were collected and immunoprecipitated with HA anti-
body. Samples were split and separated on SDS-PAGE gels and
scanned for visualization of
125I-BMP2 or immunoblotted with HA
antibody for visualization of DAF-4 or SMA-10. DAF-4 binds
125I-
BMP2, while neither SMA-10 nor the vector bind
125I-BMP2. The
bottom panel shows that both DAF-4 and SMA-10 were present in
the cell lysates.
Found at: doi:10.1371/journal.pgen.1000963.s001 (4.94 MB TIF)
Table S1 sma-10 cDNA rescues Body Size sma-10(lf) Mutants.
Body lengths of staged one-day adult hermaphrodites were
measured. sma-10(wk66) animals were non-transgenic siblings of
sma-10(wk66); texEx195 animals. The p value is the probability that
the null hypothesis, that the mean body length of the transgenic
line is the same as the sma-10(wk66) mean body length, is true. ‘‘%
sma-10(wk66)’’ is the ratio of the transgenic strain mean to the non-
transgenic sma-10(wk66) strain mean 695% confidence interval. n,
number of animals measured.
Found at: doi:10.1371/journal.pgen.1000963.s002 (0.03 MB
DOC)
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